Fellow of the Academy of Medical Sciences

Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, November 9, 2023
Science, Research, Solar eclipse of August 21, 2017, Therapy, Injection, Doctor of Philosophy, HGG, CD8, SITC, Disease, Risk, Annual general meeting, Cancer, Insurance, Break, Society for Immunotherapy of Cancer, MOS, CADL, Prostate cancer, Immune system, Antibody, Breast cancer, Pancreatic cancer, Biomarker, Safety, Patient, Administration, Cohort, Survivor, MD, Rated R, CA19-9, Development, Immunotherapy, Clinical trial, SOC, Arm, Society, Content discovery platform, Survival, Progression-free survival, HSV, HSV-1, Valaciclovir, Herpes simplex, Quarter, B cell, Vaccine, Pharmaceutical industry, NSCLC, Nature, Candel, PDAC, Fellow of the Academy of Medical Sciences

“We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.

Key Points: 
  • “We are encouraged by the recent clinical and biomarker data for CAN-2409 in NSCLC and pancreatic cancer, and CAN-3110 in recurrent HGG.
  • Research and Development Expenses: Research and development expenses were $5.8 million for the third quarter of 2023 compared to $5.4 million for the third quarter of 2022.
  • Research and development expenses included non-cash stock compensation expense of $0.3 million for both the third quarter of 2023 and the third quarter of 2022.
  • General and administrative expenses included non-cash stock compensation expense of $0.4 million for both the third quarter of 2023 and the third quarter of 2022.

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

Retrieved on: 
Saturday, November 4, 2023
Research, Arm, Society for Immunotherapy of Cancer, Intelligence, HSV, Therapy, Enlightenment, ICI, Herpes simplex virus, CADL, MD, Doctor of Philosophy, Nature, SITC, Immunotherapy, Neoplasm, Biology, Drug discovery, Machine learning, Annual general meeting, Tumor microenvironment, Bone marrow, Patient, Toxicity, Content discovery platform, Vaccine, Pharmaceutical industry, Candel, Fellow of the Academy of Medical Sciences

“We aim to leverage artificial intelligence and machine learning to expedite various aspects of drug discovery and development,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.

Key Points: 
  • “We aim to leverage artificial intelligence and machine learning to expedite various aspects of drug discovery and development,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.
  • “Tumor resistance to immunotherapy is driven by multiple mechanisms, which are heterogeneous in nature,” said Francesca Barone, MD, PhD, Chief Scientific Officer at Candel.
  • “The Alpha-201-macro1 preclinical data presented today support the utility of local delivery of an immunologically active, multimodal agent as a potential alternative to systemic therapy.
  • We are excited to leverage the enLIGHTEN™ Discovery Platform to optimize the immunostimulatory payload of this agent for activation of innate immune surveillance with the goal of maximizing its therapeutic potential.”
    Further details from the posters are available on the Candel website at: www.candeltx.com/media

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Retrieved on: 
Friday, November 3, 2023
Survival, Standard of care, Society for Immunotherapy of Cancer, CADL, Injection, Doctor of Philosophy, CA19-9, Poster, CD8, Pancreatitis, SITC, B cell, Cancer, Chemoradiotherapy, Recurrence, Annual general meeting, Pancreatic cancer, SOC, Tumor microenvironment, Therapy, Patient, Toxicity, MS, Vaccine, Pharmaceutical industry, Candel, MD, Fellow of the Academy of Medical Sciences, Immunotherapy, PDAC

Data were presented today in a poster session titled ‘Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC) at the 2023 Society for Immunotherapy (SITC) Annual Meeting.

Key Points: 
  • Data were presented today in a poster session titled ‘Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC) at the 2023 Society for Immunotherapy (SITC) Annual Meeting.
  • “Given frequent recurrence and short survival with SoC chemotherapy for non-metastatic PDAC, effective new treatment options are urgently needed,” said Garrett Nichols, MD, MS, Chief Medical Officer of Candel.
  • “We are encouraged by the improved survival associated with CAN-2409 for the treatment of borderline resectable PDAC, demonstrated for the first time in a randomized clinical trial.
  • Only one patient randomized to control SoC chemotherapy remained alive at data cut-off (alive at 43 months).

Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110

Retrieved on: 
Wednesday, October 18, 2023
Principal, Survival, Standard of care, Trial of the century, Harvard Medical School, Manuscript, Break, CADL, MD, Doctor of Philosophy, HGG, Disease, Nestin, Clinical trial, Immune system, Antibody, SOC, Tumor microenvironment, Therapy, Patient, Hospital, Glioblastoma, Toxicity, Seroconversion, Pharmaceutical industry, Vaccine, Medical imaging, Candel, Fellow of the Academy of Medical Sciences, Brigham, Nature

The publication titled “Clinical trial links oncolytic immunoactivation to survival in glioblastoma” can be accessed here .

Key Points: 
  • The publication titled “Clinical trial links oncolytic immunoactivation to survival in glioblastoma” can be accessed here .
  • Importantly, CAN-3110 treatment was associated with a significant increase in immune cells in the tumor microenvironment and in the peripheral blood.
  • Of importance, patients with recurrent HGG who had pre-existing antibodies to HSV-1 virus (66% of the patients) had a median overall survival of 14.2 months.
  • Accordingly, we observed increased diversity of the T-cell receptor repertoire after a single injection of CAN-3110 in recurrent HGG patients.

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Retrieved on: 
Wednesday, October 18, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Survival, Brentuximab vedotin, Christie, TAK, Progression-free survival, CHMP, European Commission, IRF, Committee, Bleomycin, Vinblastine, European Directive on Traditional Herbal Medicinal Products, AVD, Doxorubicin, PFS, EC, University of Manchester, Civil service commission, Hodgkin lymphoma, ADC, CD30, ABVD, Risk, Dacarbazine, University, The Christie NHS Foundation Trust, Committee for Medicinal Products for Human Use, Hatim al-Awni, Overalls, Safety, ADCETRIS, Patient, OS, Lymphoma, Medical device, Medical imaging, Pharmaceutical industry, Takeda, Fellow of the Academy of Medical Sciences

Takeda ( TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine (AVD) to treat adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma.
  • ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, a defining marker of Hodgkin lymphoma, and has been previously approved as a therapy for adult patients in Europe in six distinct indications, including those with previously untreated CD30+ Stage IV Hodgkin lymphoma.
  • The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on September 14, 2023.
  • “We are thrilled with the decision of the European Commission to approve ADCETRIS in combination with chemotherapy as a treatment for adult patients with previously untreated CD30+ Stage III Hodgkin lymphoma, particularly as up to one third of patients with Stage III & IV disease are at risk of experiencing treatment failure with current regimens,” said Awny Farajallah, M.D., head of global medical affairs oncology, Takeda.

Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, September 26, 2023
Survivor, ICIS, University, ICI, Cohort, Overalls, Survival, Clinical trial, OS, Quality of life, Lung cancer, National Cancer Institute, University of Pennsylvania, NK, Research, Toxicity, Doctor of Philosophy, Associate, PACT, ASCO, CIMAC, Patient, Perelman School of Medicine at the University of Pennsylvania, Immune system, Aggarwal, Toxic epidermal necrolysis, MPH, Therapy, CADL, Tumor microenvironment, Safety, Disease, Pharmaceutical industry, Vaccine, Candel, NSCLC, Fellow of the Academy of Medical Sciences, MD

These patients historically have had an expected median overall survival of 10-13 months (Reckamp K et al.

Key Points: 
  • These patients historically have had an expected median overall survival of 10-13 months (Reckamp K et al.
  • Candel expects to share topline overall survival data for Cohort 2 in the second quarter of 2024, assuming mature data at that time.
  • “We are very encouraged by the initial survival data, particularly for Cohort 2 which enrolled patients whose disease progressed despite receiving anti-PD(L)1 treatment.
  • I look forward to the maturation of these overall survival data and expected readout in Q2 2024.”

The Jackson Laboratory names Meghan Finn Vice President and Chief Communications Officer

Retrieved on: 
Wednesday, September 20, 2023
Communication, Advertising, Society, Genetics, National Multiple Sclerosis Society, Biomedical Research, Research, Genomics, Breast, Iona University, Jackson Laboratory, Finn, BCRF, Fellow of the Academy of Medical Sciences, Council, JAX, Breast Cancer Research Foundation, Growth, Health, Breast cancer, Management

FARMINGTON, Conn., Sept. 20, 2023 /PRNewswire/ -- Meghan Finn has joined The Jackson Laboratory, an independent, nonprofit biomedical research institution, as Vice President and Chief Communications Officer.

Key Points: 
  • FARMINGTON, Conn., Sept. 20, 2023 /PRNewswire/ -- Meghan Finn has joined The Jackson Laboratory, an independent, nonprofit biomedical research institution, as Vice President and Chief Communications Officer.
  • "We are thrilled to welcome Meghan Finn as JAX's newly appointed vice president and chief communications officer," said Lon Cardon , Ph.D., FMedSci, president and CEO.
  • Prior to BCRF, Meghan was employed at the National Multiple Sclerosis Society, where she held a variety of positions, most recently vice president of brand and communications.
  • A member of Chief and the Forbes Nonprofit Council, Meghan also serves on the President's Council of Northwell Health Northern Westchester Hospital.

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Retrieved on: 
Wednesday, September 13, 2023
Auckland City Hospital, KOL, MNZM, FRCP, University, MBBS, University of Auckland, Q&A, Old Road Campus, Cancer, Nuffield Department of Population Health, Doctor of Philosophy, Autoimmunity, Small RNA, Medical research, Hepatology, Patient, Immune system, Safety, Vaccitech, HBV, Nivolumab, University of Oxford, Disease, MVA, Vaccine, FRACP, Bachelor of Medicine, Bachelor of Surgery, Hepatitis, Fellow of the Academy of Medical Sciences, MD

Details are as follows:

Key Points: 
  • Details are as follows:
    To register for the event, click here .
  • The Vaccitech management team will provide a clinical overview of VTP-300, the first antigen-specific immunotherapy that has been shown to induce sustained reductions in Hepatitis B surface antigen, a marker of the disease.
  • Vaccitech is studying VTP-300, including in combination with siRNA and low-dose anti-PD-1 antibodies, as part of the search for a regimen that could lead to a potential functional cure for HBV.
  • A live Q&A session will follow the formal presentations.

Keela Johnson of Giarmarco, Mullins & Horton, P.C. has been selected to become a fellow of the American Academy of Matrimonial Lawyers

Retrieved on: 
Tuesday, September 12, 2023
P.C, Fellow of the Academy of Medical Sciences, Lawyer, American Academy, Family, Divorce, Fellow, Practice of law

TROY, Mich. and DETROIT, Sept. 12, 2023 /PRNewswire/ -- Keela Johnson has been selected to become a fellow of the American Academy of Matrimonial Lawyers.

Key Points: 
  • TROY, Mich. and DETROIT, Sept. 12, 2023 /PRNewswire/ -- Keela Johnson has been selected to become a fellow of the American Academy of Matrimonial Lawyers.
  • The American Academy of Matrimonial Lawyers is a nationally distinguished and highly selective group of attorneys considered experts in matrimonial and family law.
  • Lawyers being selected for "Fellowship" are recognized and respected by the bench and bar as the leaders in the field.
  • By demonstrating the highest standards of matrimonial practice, Fellows of the Academy have set the standard for the matrimonial bar.

Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Wednesday, September 6, 2023
Candel, Webcast, Therapy, CADL, MD, Patient, Conference, News, Doctor of Philosophy, Pharmaceutical industry, Broadcasting, Fellow of the Academy of Medical Sciences

NEEDHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023, in New York City.

Key Points: 
  • NEEDHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023, in New York City.
  • A live webcast of the presentation will be available by selecting Events and Presentations under the News & Events tab in the Investors section on candeltx.com .
  • A replay of the webcast will be archived for up to 90 days following the presentation date.